Biotechnology in the United Kingdom
Published: August 2013 · Publisher: MarketLine
Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Kingdom biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The UK biotechnology market had total revenues of $8.7bn in 2012, representing a compound annual growth rate (CAGR) of 7.1% between 2008 and 2012.
*With 282 biotech companies, the UK comes second in Europe for company density, behind Germany (397) and followed by Italy (248).
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.4% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $11.8bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the United Kingdom economy
Key Questions Answered
What was the size of the United Kingdom biotechnology market by value in 2012?
What will be the size of the United Kingdom biotechnology market in 2017?
What factors are affecting the strength of competition in the United Kingdom biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up the United Kingdom's biotechnology market?
Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Kingdom biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The UK biotechnology market had total revenues of $8.7bn in 2012, representing a compound annual growth rate (CAGR) of 7.1% between 2008 and 2012.
*With 282 biotech companies, the UK comes second in Europe for company density, behind Germany (397) and followed by Italy (248).
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.4% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $11.8bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the United Kingdom economy
Key Questions Answered
What was the size of the United Kingdom biotechnology market by value in 2012?
What will be the size of the United Kingdom biotechnology market in 2017?
What factors are affecting the strength of competition in the United Kingdom biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up the United Kingdom's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
GE Healthcare, Novartis AG, Sanofi and AstraZeneca PLC
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
GE Healthcare 19
Novartis AG 20
Sanofi 23
AstraZeneca PLC 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: United Kingdom biotechnology market value: $ billion, 2008–12 8
Table 2: United Kingdom biotechnology market category segmentation: $ billion, 2012 9
Table 3: United Kingdom biotechnology market geography segmentation: $ billion, 2012 10
Table 4: United Kingdom biotechnology market value forecast: $ billion, 2012–17 11
Table 5: GE Healthcare: key facts 19
Table 6: Novartis AG: key facts 20
Table 7: Novartis AG: key financials ($) 21
Table 8: Novartis AG: key financial ratios 21
Table 9: Sanofi: key facts 23
Table 10: Sanofi: key financials ($) 24
Table 11: Sanofi: key financials (€) 24
Table 12: Sanofi: key financial ratios 24
Table 13: AstraZeneca PLC: key facts 26
Table 14: AstraZeneca PLC: key financials ($) 27
Table 15: AstraZeneca PLC: key financial ratios 27
Table 16: United Kingdom size of population (million), 2008–12 29
Table 17: United Kingdom gdp (constant 2000 prices, $ billion), 2008–12 29
Table 18: United Kingdom gdp (current prices, $ billion), 2008–12 29
Table 19: United Kingdom inflation, 2008–12 30
Table 20: United Kingdom consumer price index (absolute), 2008–12 30
Table 21: United Kingdom exchange rate, 2008–12 30
LIST OF FIGURES
Figure 1: United Kingdom biotechnology market value: $ billion, 2008–12 8
Figure 2: United Kingdom biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: United Kingdom biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: United Kingdom biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in the United Kingdom, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in the United Kingdom, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in the United Kingdom, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in the United Kingdom, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in the United Kingdom, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in the United Kingdom, 2012 18
Figure 11: Novartis AG: revenues & profitability 22
Figure 12: Novartis AG: assets & liabilities 22
Figure 13: Sanofi: revenues & profitability 25
Figure 14: Sanofi: assets & liabilities 25
Figure 15: AstraZeneca PLC: revenues & profitability 28
Figure 16: AstraZeneca PLC: assets & liabilities 28
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
GE Healthcare 19
Novartis AG 20
Sanofi 23
AstraZeneca PLC 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: United Kingdom biotechnology market value: $ billion, 2008–12 8
Table 2: United Kingdom biotechnology market category segmentation: $ billion, 2012 9
Table 3: United Kingdom biotechnology market geography segmentation: $ billion, 2012 10
Table 4: United Kingdom biotechnology market value forecast: $ billion, 2012–17 11
Table 5: GE Healthcare: key facts 19
Table 6: Novartis AG: key facts 20
Table 7: Novartis AG: key financials ($) 21
Table 8: Novartis AG: key financial ratios 21
Table 9: Sanofi: key facts 23
Table 10: Sanofi: key financials ($) 24
Table 11: Sanofi: key financials (€) 24
Table 12: Sanofi: key financial ratios 24
Table 13: AstraZeneca PLC: key facts 26
Table 14: AstraZeneca PLC: key financials ($) 27
Table 15: AstraZeneca PLC: key financial ratios 27
Table 16: United Kingdom size of population (million), 2008–12 29
Table 17: United Kingdom gdp (constant 2000 prices, $ billion), 2008–12 29
Table 18: United Kingdom gdp (current prices, $ billion), 2008–12 29
Table 19: United Kingdom inflation, 2008–12 30
Table 20: United Kingdom consumer price index (absolute), 2008–12 30
Table 21: United Kingdom exchange rate, 2008–12 30
LIST OF FIGURES
Figure 1: United Kingdom biotechnology market value: $ billion, 2008–12 8
Figure 2: United Kingdom biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: United Kingdom biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: United Kingdom biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in the United Kingdom, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in the United Kingdom, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in the United Kingdom, 2012 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in the United Kingdom, 2012 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in the United Kingdom, 2012 17
Figure 10: Drivers of degree of rivalry in the biotechnology market in the United Kingdom, 2012 18
Figure 11: Novartis AG: revenues & profitability 22
Figure 12: Novartis AG: assets & liabilities 22
Figure 13: Sanofi: revenues & profitability 25
Figure 14: Sanofi: assets & liabilities 25
Figure 15: AstraZeneca PLC: revenues & profitability 28
Figure 16: AstraZeneca PLC: assets & liabilities 28
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.